Market Research Logo

Actinic (Solar) Keratosis - Pipeline Review, H2 2016

Introduction
Global Markets Direct Report Coverage
Actinic (Solar) Keratosis Overview
Therapeutics Development
Pipeline Products for Actinic (Solar) Keratosis - Overview
Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis
Actinic (Solar) Keratosis - Therapeutics under Development by Companies
Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes
Actinic (Solar) Keratosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Actinic (Solar) Keratosis - Products under Development by Companies
Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
3M Drug Delivery Systems
Athenex, Inc.
Digna Biotech, S.L.
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Galderma S.A.
Laboratories Ojer Pharma S.L.
LEO Pharma A/S
Novartis AG
Oncology Research International Limited
Promius Pharma, LLC
Spherium Biomed S.L.
Valeant Pharmaceuticals International, Inc.
Vectura Group Plc
Actinic (Solar) Keratosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-17137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
celecoxib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFD-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
disitertide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrogen peroxide + sulindac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDP-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDP-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LEO-43204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LFX-453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORIL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKP-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Protein Kinase C for Actinic Keratosis and Non-melanoma Skin Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-12054 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VDA-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Actinic (Solar) Keratosis - Dormant Projects
Actinic (Solar) Keratosis - Discontinued Products
Actinic (Solar) Keratosis - Product Development Milestones
Featured News & Press Releases
Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Actinic (Solar) Keratosis, H2 2016
Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H2 2016
Actinic (Solar) Keratosis - Pipeline by Athenex, Inc., H2 2016
Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H2 2016
Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016
Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H2 2016
Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma S.L., H2 2016
Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H2 2016
Actinic (Solar) Keratosis - Pipeline by Novartis AG, H2 2016
Actinic (Solar) Keratosis - Pipeline by Oncology Research International Limited, H2 2016
Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H2 2016
Actinic (Solar) Keratosis - Pipeline by Spherium Biomed S.L., H2 2016
Actinic (Solar) Keratosis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
Actinic (Solar) Keratosis - Pipeline by Vectura Group Plc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Actinic (Solar) Keratosis - Dormant Projects, H2 2016
Actinic (Solar) Keratosis - Dormant Projects (Contd..1), H2 2016
Actinic (Solar) Keratosis - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Actinic (Solar) Keratosis, H2 2016
Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Actinic (Solar) Keratosis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Actinic (Solar) Keratosis - Pipeline Review, H2 2016’, provides an overview of the Actinic (Solar) Keratosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis
    • The report reviews pipeline therapeutics for Actinic (Solar) Keratosis by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Actinic (Solar) Keratosis therapeutics and enlists all their major and minor projects
    • The report assesses Actinic (Solar) Keratosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report

    ;